ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. More Details
No risks detected for CXRX.F from our risk checks.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has ADVANZ PHARMA's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CXRX.F is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: CXRX.F's weekly volatility has decreased from 36% to 2% over the past year.
7 Day Return
1 Year Return
Return vs Industry: CXRX.F exceeded the US Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: CXRX.F exceeded the US Market which returned 51.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ADVANZ PHARMA's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ADVANZ PHARMA undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CXRX.F ($16.8) is trading below our estimate of fair value ($36.72)
Significantly Below Fair Value: CXRX.F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CXRX.F is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: CXRX.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CXRX.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CXRX.F is overvalued based on its PB Ratio (108.3x) compared to the US Pharmaceuticals industry average (3.6x).
How is ADVANZ PHARMA forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ADVANZ PHARMA has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has ADVANZ PHARMA performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CXRX.F is currently unprofitable.
Growing Profit Margin: CXRX.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CXRX.F is unprofitable, but has reduced losses over the past 5 years at a rate of 30.2% per year.
Accelerating Growth: Unable to compare CXRX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CXRX.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.6%).
Return on Equity
High ROE: CXRX.F has a negative Return on Equity (-986.79%), as it is currently unprofitable.
How is ADVANZ PHARMA's financial position?
Financial Position Analysis
Short Term Liabilities: CXRX.F's short term assets ($449.5M) exceed its short term liabilities ($210.1M).
Long Term Liabilities: CXRX.F's short term assets ($449.5M) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: CXRX.F's debt to equity ratio (17459%) is considered high.
Reducing Debt: CXRX.F's debt to equity ratio has increased from 287.4% to 17459% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CXRX.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CXRX.F is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 3.8% per year.
What is ADVANZ PHARMA current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CXRX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CXRX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CXRX.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CXRX.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CXRX.F is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CXRX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Graeme Duncan (45 yo)
Mr. Graeme Neville Duncan has served as a Chief Executive Officer at ADVANZ PHARMA Corp. since June 26, 2018 and has served as its Director since 2018. He serves as Executive Director of ADVANZ PHARMA Corp...
CEO Compensation Analysis
Compensation vs Market: Graeme's total compensation ($USD1.62M) is below average for companies of similar size in the US market ($USD2.34M).
Compensation vs Earnings: Graeme's compensation has been consistent with company performance over the past year.
Experienced Management: CXRX.F's management team is considered experienced (2.9 years average tenure).
Experienced Board: CXRX.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ADVANZ PHARMA Corp. Limited's company bio, employee growth, exchange listings and data sources
- Name: ADVANZ PHARMA Corp. Limited
- Ticker: CXRX.F
- Exchange: OTCPK
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$821.747m
- Shares outstanding: 48.91m
- Website: https://www.advanzpharma.com
Number of Employees
- ADVANZ PHARMA Corp. Limited
- Capital House
- 1st Floor
- Greater London
- EC4N 7BL
- United Kingdom
ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segmen...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 22:03|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.